About UCSF Partnerships

UCSF Innovation Ventures

UCSF partners with Autobahn Labs

Pamela England, PhD
UCSF Professor

AUTOBAHN LABS

Drug Discovery Accelerator Bringing

- *Expertise*
- *Global drug discovery technology and capabilities*
- *Financial capital*

➢ *3 Options to license from UCSF*
➢ *1 Licensed technology from UCSF*

UCSF Innovation Ventures

Want to know more?

Amy Gryshuk, PhD

Associate Director, Office of Strategic Alliances, UCSF Innovation Ventures

AUTOBAHN LABS

UCSF

UCSF Innovation Ventures

UCSF as a founding academic collaborator of PICI

Kole Roybal, PhD
Director of UCSF PICI

Julia Carnevale, MD
Co-Director of UCSF PICI

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

Cancer research and breakthrough immune therapies accelerator

- *Brings top researchers together*
- *Provides resources*
- *Eliminates barriers*

UCSF Innovation Ventures

Want to know more?

Olivia Roberson, PhD

Sr. Alliance and Business Development Manager, UCSF Innovation Ventures

Gemma Rooney, PhD

Assistant Director, Strategic Partnerships & Licensing, UCSF Innovation Ventures

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

UCSF

UCSF Innovation Ventures

UCSF partners with Foundery Innovations

Max Krummel, PhD

UCSF Professor

Foundery

Accelerator for transformative immunotherapies

- *Immunotherapy venture studio*
- *Focus on company creation*
- *Efficient validation and translation of early drug concepts*

UCSF Innovation Ventures

Want to know more?

Aleksandra Kijac, PhD

Business Development and
Strategic Alliance Manager, UCSF
Innovation Ventures

Foundery

UCSF

UCSF Innovation Ventures

UCSF & HS Progress

Haley Naik, MD, MHSc, FAAD

UCSF Co-founder

HS PROGRESS

The Hidradenitis Suppurativa PRospective Observational REgistry and bioSpecimen repoSitory

- *Multicenter*
- *Longitudinal*

Mission to improve the lives of people living with Hidradenitis Suppurativa

UCSF Innovation Ventures

Want to know more?

Peter Kotsonis, PhD

Assistant Vice Chancellor of Business Development,
Innovation and Partnerships, UCSF Innovation Ventures

HS PROGRESS

Mission to improve the lives of people living with Hidradenitis Suppurativa

UCSF Innovation Ventures

UCSF partners with Eli Lilly and Company

Max Krummel, PhD

UCSF Professor

Lilly | UCSF immunoprofiler INITIATIVE

Working toward new insights into autoimmune diseases

- *Proteomic, transcriptomic, epigenomic and structural data*
- *Freshly collected tissue*
- *Matched peripheral blood samples*
- *Clinically well-annotated patients*

UCSF Innovation Ventures

Want to know more?

Aleksandra Kijac, PhD

Business Development and Strategic Alliance Manager, UCSF Innovation Ventures

Lilly

UCSF immunoprofiler INITIATIVE

UCSF Innovation Ventures

The Weill Neurohub

University of California San Francisco

Berkeley UNIVERSITY OF CALIFORNIA

UNIVERSITY of WASHINGTON

Weill Neurohub

Accelerating the development of new treatments for neurological and psychiatric disease

- *Seed funding for novel research ideas*
- *Interdisciplinary and collaborative projects*
- *Focus on near-term transformational potential*

UCSF Innovation Ventures

The Alliance for Therapies in Neuroscience

Stephen Hauser, MD

Director of UCSF Weill Institute for Neuroscience

Genentech
A Member of the Roche Group

Roche

Weill Neurohub

Accelerating the development of new therapeutics

- *Long-term research partnership*
- *Centered on brain diseases and disorders of the central nervous system (CNS)*

UCSF Innovation Ventures

Want to know more?

Amy Gryshuk, PhD

Associate Director, Office of Strategic Alliances, UCSF Innovation Ventures

Genentech
A Member of the Roche Group

Roche

Weill Neurohub

UCSF Innovation Ventures

Arc Institute Accelerating Research

Silvana Konermann
Executive Director and Core Investigator

Patrick Hsu
Co-Founder and Core Investigator

Arc Institute

Nonprofit research organization

- *Curiosity-driven and goal-oriented research with a focus on complex diseases, including neurodegeneration, cancer and immune dysfunction.*
- *Operates in collaboration with Stanford University, the University of California, Berkeley, and the University of California, San Francisco.*

UCSF Innovation Ventures

Want to know more?

Amy Gryshuk, PhD

Associate Director,
Office of Strategic Alliances
UCSF Innovation Ventures

Gemma Rooney, PhD

Assistant Director, Strategic Partnerships
& Licensing, UCSF Innovation Ventures

Arc Institute

UCSF

UCSF Innovation Ventures

Chan Zuckerberg Biohub Network
Driving Disruptive Innovation

Steve Quake, PhD
Head of Science,
Chan Zuckerberg Initiative

Joe Derisi, PhD
President,
CZ Biohub San Francisco

CHAN ZUCKERBERG
Biohub Network

Group of nonprofit research institutes bringing together scientists, engineers, and physicians

- *Goal of pursuing grand scientific challenges over a 10-15 year timeframe.*
- *Focuses on understanding the mysteries of the cell and how cells interact within systems as well as developing new technologies leading to diagnostics and therapies.*

UCSF Innovation Ventures

Want to know more?

Gemma Rooney, PhD

Assistant Director, Strategic Partnerships & Licensing, UCSF Innovation Ventures

CHAN ZUCKERBERG Biohub Network

UCSF

UCSF Innovation Ventures

UCSF & Laboratory for Genomics Research (LGR)

UCSF
University of California
San Francisco

Berkeley
UNIVERSITY OF CALIFORNIA

GSK

Laboratory
for Genomics
Research

*The aim is to **deepen our understanding of genetics, discover new targets, and create next-generation technologies** at scale that will become future standard practice for the pharmaceutical industry.*

UCSF Innovation Ventures

UCSF partners with GSK

Laboratory for Genomics Research

Next-generation CRISPR-based technologies at scale

- *Develop and optimize new CRISPR technologies*
- *Invest in automation platforms for large-scale CRISPR screens*
- *Deepen our understanding of genetics and discover new targets*

UCSF Innovation Ventures

Want to know more?

Amy Gryshuk, PhD

Associate Director,
Office of Strategic Alliances
UCSF Innovation Ventures

Monica Ravanello, PhD

Senior Strategic Partnerships &
Intellectual Property Manager, UCSF
Innovation Ventures

UCSF University of California San Francisco

GSK

Berkeley UNIVERSITY OF CALIFORNIA

UCSF

University of California
San Francisco

UCSF Startups

Therapeutics

Targeting Mucus Plugs to Improve Lung Health

John Fahy, MD, MS
Co-founder, Aer Therapeutics
UCSF Pulmonologist and Innovator

PROBLEM:

- Between 30% and 50% of COPD patients with severe and very severe COPD suffer from airway obstruction caused by mucus plugs.
- Mucus plugs reduce lung function and diminish quality of life.
- There are no drugs approved to effectively liquify mucus plugs (mucolytics) in patients with COPD.

SOLUTION:

- Fexlamose is a novel inhaled best-in-class therapeutic candidate designed to improve lung health by liquifying mucus plugs.
- Fexlamose is a thiol-modified carbohydrate (“thiol-saccharide”) which cleaves mucine disulfide bridges to liquefy (“lyse”) mucus plugs.

FUNDING:

- >$18M in NIH funding; $36M Series A (Canaan, Orbimed, Hatteras)

PROGRESS

- Phase 1 studies in healthy volunteers completed
- Phase 2 POC started in q4 2024
- Top line efficacy data expected in q1 2026

LEARN MORE:

We drive innovation in oncology and solid organ diseases through development of organ selective therapy for early interception and treatment of the prostate disease

Pamela Munster, MD
Founder and CSO,
Alessa Therapeutics
UCSF Professor of Medicine and Innovator



Pre-implant seed

Post-implantation seeds in cancerous human prostate



PROBLEM:

- 1 in 6 men will be afflicted with prostate cancer during their lifetimes, 30k will die every year.
- 12M men in the US seek treatment for benign prostate hyperplasia every year.
- Current therapies mainly centered around systemic testosterone ablation.

SOLUTION:

- Implant and delivery systems for localized, sustained drug delivery without systemic side effects.
- Focused on treatment of localized prostate cancer and BPH.
- Robust pipeline of target specific organ selective strategies.

TRACTION:

- $15M in seed funding led by Mission BioCapital joined by Johnson & Johnson
- Ongoing clinical trial with Enolen

LEARN MORE:

Reimagining Genome Regulation

Luke Gilbert, PhD
Co-founder, Chroma Medicine
UCSF Professor and Innovator

PROBLEM:

- To build single dose therapeutics that durably control expression of human genes.

SOLUTION:

- Single-dose genomic medicines that harness epigenetics for durable and heritable gene silencing.
- A modular platform for epigenetic editing to address a wide range of complex diseases.



TRACTION:

- Chroma Medicine and Nvelop Therapeutics **UNITE** to Form **nChroma Bio,** Securing $75 Million to Accelerate Genetic Medicines
- Chroma Medicine Demonstrates Robust and Durable HBV Silencing with CRMA-1001
- >$250M in Funding

LEARN MORE:

Expanding Protein Degradation to Membrane and Extracellular Targets

Jim Wells, PhD
Co-Founder, EpiBiologics
Founding Director, Small Molecule Discovery Center (SMDC)
Director, Antibiome Center
UCSF Innovator



PROBLEM:

- First generation protein degradation approaches target intracellular proteins only.
- 40% of the proteome is unaccounted for.
- Better targeted therapies are still needed.
- Need modalities that can avoid complex manufacturing and short half-life and localize degradation to disease tissue.

SOLUTION:

- EpiTAC platform leverages bispecific antibodies and a novel atlas of tissue-selective degrader receptors to drive strong efficacy
- Bispecific antibodies are scalable, manufacturable, and have good pharmacological properties that enable long half-life and durable responses.

TRACTION:

- Demonstrated POC for soluble and membrane targets, including GPCRs
- Raised >$70M in Series A, initiating Series B to move into the clinic

LEARN MORE:

Redefining Drug Discovery for Rare Genetic Epilepsies

Scott C. Baraban, PhD
Co-founder, Epygenix Therapeutics
Professor, William K. Bowes Jr. Endowed Chair in Neuroscience Research
UCSF Innovator

PROBLEM

- 30-40% of epilepsy is caused by genetic mutation.
- Most genetic epilepsies are pharmaco-resistant, emerge early in life & are life-threatening.
- Existing antiepileptic medications were not identified using genetic epilepsy models.

SOLUTION

- 'Aquarium-to-Bedside' drug discovery using genetically modified zebrafish models in high-throughput phenotype-based drug screening.

TRACTION

- Epygenix Therapeutics, Inc **ACQUIRED** by Harmony Biosciences in April 2024
- >$35M in seed funding
- Six drug candidates licensed from UCSF w/ method-of-use and formulation IP

LEARN MORE:

Targeted Gene Therapy to Transform the Lives of People Living with Severe Genetic Diseases

Navneet Matharu, Ph.D.
Co-founder/CSO, Regel Tx
UCSF Assistant (Adjunct) Professor
IGI-WIES fellow

Nadav Ahituv, Ph.D.
Co-founder Regel Tx
UCSF Professor, Bioengineering
Director, Institute for Human Genetics

PROBLEM:

- Disease modifying therapies for haploinsufficient disorders are lacking.
- Approx 600 such disorders have high unmet need.
- Targeted genetic therapies are needed.



SOLUTION:

- Clinical vector with a dCas module and an engineered enhancer.
- Targeted delivery with a one-time injection in the affected system.
- Restricts the intervention to the affected cells
- The dCas module normalizes the level of gene expression.

TRACTION:

- Raised $6M seed + BD partnership
- 3 programs under a Research Collaboration and Option Agreement with Sarepta Therapeutics

LEARN MORE:

Unique Platform to go from Sequence to Systems to Drugs

UCSF Co-founders

Nevan Krogan, PhD
UCSF Professor

Sourav Bandyopadhyah, PhD
UCSF Professor

Natalia Jura, PhD
UCSF Professor



PROBLEM:

- Drug discovery and development is LONG (10-15yrs), COSTLY ($1-2 billion) and HIGH-RISK with a 90% clinical failure rate due to the lack of clinical efficacy, unmanageable toxicity, and poor drug-like properties

SOLUTION:

- Combining multimodal data from several advanced technologies: from disease associated genes to causative protein networks
- Identifying convergent biological pathways driven by disease causing proteins
- Discovering new high-confidence actionable therapeutic targets and integrating AI for novel therapeutic discovery

TRACTION:

- $78M Series A funded in 2022

LEARN MORE:

Developing Live Biotherapeutics Targeting Core Drivers of Disease

Nikole Kimes, PhD
Co-founder and CEO,
Siolta Therapeutics
UCSF Inventor & PhD
Postdoc Alum



PROBLEM:

- Addressing the underlying cause of IgE-mediated diseases, including atopic dermatitis, food allergy, allergic asthma and allergic rhinitis
- Developing live biotherapeutics that target the core drivers of disease through immunomodulation.

SOLUTION:

- Patient-centric platform.
- Microbiome data analysis, machine learning, anaerobic microbiology.
- Optimizes multi-strain live biotherapeutics to prevent/treat disease.

TRACTION:

- $12M Series C for clinical development co-led by SymBiosis and Khosla Ventures
- $50M in funding

LEARN MORE:

Universal AAV Immuno-Gene Therapy for Cancer

Nicole K. Paulk, PhD
CEO, Founder, President
Siren Biotechnology
Prior UCSF Professor





PROBLEM:

- No effective therapies for brain cancers

TRACTION:

- Announced partnership with Catalent for AAV gene therapy manufacturing for cancer
- Awarded $4M in grant funding from California Institute for Regenerative Medicine (CIRM)
- Awarded ODD and RPD FDA designations

SOLUTION:

- Combining AAV gene therapy and cytokine immunotherapy into a single, reimagined modality overcomes key challenges in destroying tumor cells and eliciting anti-tumor immunity.
- 1st AAV drug product that can treat more than one disease.
- A universal gene therapy reduces clinical development times, manufacturing timelines, and capital needs per program.
- Countless solid tumor cancer patients will be eligible regardless of tumor type or mutations with this breakthrough approach.

LEARN MORE:

Exploiting Ferro-Addiction in Tumors with Proprietary Ferrous Iron REactive (FIRE) Linker Technology

tatara therapeutics

UCSF

UCSF Co-founders

Adam Renslo, PhD
Tatara Therapeutics
UCSF Professor and Associate Dean for Entrepreneurship

Eric Collisson, MD
Tatara Therapeutics
Oncologist and Professor Fred Hutchinson Cancer Center (Formerly UCSF)

PROBLEM:

- Cancer therapeutics act systemically, with systemic toxicities that reduce therapeutic index and limit efficacy.

SOLUTION:

Tumor-conditional activation of linkers for prodrug and ADC modalities

- Ferrous Iron REactive (FIRE) linker technology



- Broad scope of utility across multiple Tx modalities
- Current focus on topoisomerase-I payload delivery

TRACTION:

- ~$6M in VC and home office investment to date
- Multiple patent families: US 11,014,955; 11,072,594; WO 2023/049829

LEARN MORE:

Immunotherapy

Programmable Cell Therapy to Defeat Solid Tumors

UCSF Co-founders

Alexander Marson, MD, PhD
Co-founder, ArsenalBio
UCSF Professor and Innovator

Kole Roybal, PhD
Co-founder, ArsenalBio
UCSF Professor and Innovator

PROBLEM:

- Solid tumors are complex and refractory to most treatment regimens.





SOLUTION:

- Deploying the combination of CITE editing, a toolkit of synthetic receptors for tumor recognition and a combination of T cell enhancements to improve therapeutic activity.

TRACTION:

- $325M Series C funding in September 2024
- AB-2100 for treatment of Kidney cancer continues to dose patients in a phase 1 trial. Advancing multiple preclinical candidates for solid tumors, including AB-300 for metastatic prostate cancer.
- Collaborations with BMS and Genentech
- >$500M in Equity Funding and Revenues

LEARN MORE:

DECIDUOUS THERAPEUTICS

Immune Therapy to Extend Healthspan

UCSF

Anil Bhushan, PhD
Scientific Co-founder,
Deciduous Therapeutics
UCSF Professor and Innovator



PROBLEM:

- Killing pathologic senescent cells improves many preclinical age-related disease models.
- Identifying a target that is safe for systemic administration remains a challenge.

SOLUTION:

- Deciduous eliminates senescent cells by re-activating the failed immune system's surveillance mechanism in diseased patients.
- A single systemic dose improves endpoints in a pulmonary fibrosis preclinical model, as well as a diet-induced obesity metabolic disease model in under two weeks.

TRACTION:

- >$18M in funding
- Mechanism discovery published in *Med* titled, "Invariant natural killer T cells coordinate removal of senescent cells"

LEARN MORE:

Next-Generation Immunotherapies Harnessing Myeloid Biology

Ron Vale, PhD
Founder, Myeloid Therapeutics
UCSF Professor and Innovator

PROBLEM:

- Sustained medical benefit is still not achieved for majority of patients with advanced solid tumors

SOLUTION:

- Myeloid cells can make up to 75% of tumor mass
- *In-vivo* mRNA delivery platform targeting myeloid cells
- Retrotransposon-mediated gene-insertion technology for delivery of larger genetic sequences



TRACTION:

- Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors
- >$120M in Funding

LEARN MORE:

Restoring Balance is Key to Unlocking Cures

Jeffrey Bluestone, PhD
Co-founder, Sonoma Biotherapeutics
CEO, President and Emeritus
UCSF Professor and Innovator

Qizhi Tang, PhD
Scientific Advisor, Sonoma Biotherapeutics
UCSF Professor, Surgery

PROBLEM:

- There are many autoimmune diseases which together account for among the highest rate of medication expenditures in the US.
- RA alone contributes an estimated $22.3B[1].



SOLUTION:

- One time treatment focused on autoimmune and inflammatory diseases.
- A unique platform combining engineered Treg cells with a drug that depletes/deactivates Teff cells at the site of disease.

TRACTION:

- Recent $45M Milestone payment received from Regeneron under ongoing collaboration
- >$450M in Funding

LEARN MORE:

Medical Devices and Digital Health

From genes to phenotype in every research pipeline

Charlotte Nelson
Co-founder & CEO,
Mate Bioservices
UCSF BMI Alum

Sergio Baranzini
Co-founder, Mate Bioservices
UCSF Professor of Neurology

PROBLEM:

- Biological complexity is resisted instead of embraced in biomedical research.
- Data and knowledge silos impede scientific breakthroughs.



SOLUTION:

- Mate's core engine offers unparalleled data access - harmonized, normalized, & seamlessly packaged.
- Intuitive explainable AI interfaces for wet and dry lab scientists tackle months of research in minutes.

TRACTION:

- Supported by the NSF Convergence Accelerator
- Leveraged by NASA, academic institutions, and pharma companies of all sizes, worldwide

LEARN MORE:

SIRA MEDICAL

We Bridge The Gap Between Imaging And Reality

UCSF

Jesse Courtier, MD
Co-founder, Sira Medical
UCSF Chief of Pediatric Radiology and Innovator

SOLUTION:

- Augmented reality software to help with preoperative planning by providing patient-specific high fidelity 3D holograms.

PROBLEM:

- Surgeons have difficulty translating radiology information into real world patients for preoperative planning.

TRACTION:

- Received FDA 510k clearance for preoperative planning software
- Nearly $1M from grants, accelerators, and VC funding
- Deployed in 150 surgeries at UCSF
- Completed 5 pilots, 3 ongoing project with UC Davis, and 2 publications in 2024
- IP: developed proprietary software and model creation methods
- Finalist UCSF Digital Health Award

LEARN MORE:

Trial Library

A technology company on a mission to advance health equity by expanding access to cancer precision medicine

UCSF

Hala Borno,MD
CEO & Founder,
Trial Library
UCSF Associate Professor
Medical Oncologist

PROBLEM:

- Oncology clinical trial recruitment remains inefficient, with only 13% of US oncologists participating in research.
- Inequities persist and <7% eligible patients enroll on trials.

SOLUTION:

- Trial Library's platform enables rapid healthcare provider decision support and patient navigation to accelerate oncology recruitment.



TRACTION:

- Healthcare provider network >1500 physicians in the United States
- Preferred recruitment platform for several large global biopharma clients.

LEARN MORE:

Diagnostics

Short-cutting the Diagnostic Journey through Metagenomic Next-Generation Sequencing

UCSF Co-Founders

Joe DeRisi, PhD
UCSF Professor

Michael Wilson, MD
UCSF Professor

Charles Chiu, MD, PhD
UCSF Professor

PROBLEM:

- Hospitalization of a meningitis and encephalitis case can last up to 25 days, with average costs of nearly $20,000 per day.
- >60% of cases are due to infection, and patients often undergo 40+ different tests in the search for etiology.
- Each test takes days to weeks, and only detects a handful of pathogens, resulting in delayed treatment, unnecessary testing, and extended lengths of stay.

SOLUTION:

- Comprehensive detection of all viruses, bacteria, parasites, and fungi at once from a single sample.
- Rapid, powerful metagenomics testing platform that returns results to clinicians in 48h.

delvedetect
CEREBROSPINAL FLUID

TRACTION:

- With $35M Series A, Delve Bio stands up a robust clinical and commercial operation to bring mNGS to more patients nationwide.
- Delve Bio launches Delve Detect, its flagship mNGS testing service that detects pathogens in cerebrospinal fluid.
- Premier top-tier customer base (~300 hospitals) with annual volumes increasing YoY (40% CAGR).
- Seven-year, real-world evidence of clinical adoption of mNGS published in Nature Medicine

LEARN MORE:

Improving IVF Success with Advanced Embryo Selection Technology

Paolo Rinaudo, MD, PhD
Cofounder, EmbryoDx Solutions
Obstetrics/Gynecology and Reproductive Endocrinologist at UCSF



PROBLEM:

- Inability to identify the healthiest embryos to transfer, leading to low success rates of IVF and need for multiple IVF cycles.

SOLUTION:

- Novel biomarkers indicative of embryonic health, laying the foundation for a safe and reliable device tailored for embryo selection.
- State-of-the-art technology that has the potential to dramatically increase IVF success rates.

STATUS:

- Spinning out

LEARN MORE:

Exai Bio: A cell-free RNA- & AI-based liquid biopsy platform positioned to play a central role in the next phase of breast cancer management

Hani Goodarzi, PhD
Co-founder & Scientific Advisor, Exai Bio
UCSF Associate Professor and Arc Institute Core Investigator

PROBLEM:

- >40% of women over age 40 have dense breast tissue and these women have a higher overall risk of developing breast cancer
- Mammograms have significant limitations for women with dense breasts leading to missed cancers
- Growing awareness of mammogram limitations due to FDA guidelines
- ctDNA has clear plateaus in detecting early-stage breast cancer

SOLUTION:

- Our co-founders at UCSF discovered a novel class of small RNA biomarkers, called oncRNAs, that are actively shed by living cancer cells into the blood.
- Generative AI Illuminates cancer specific patterns of RNAs in blood enabling a highly effective early detection solution.
- Exai's platform detects breast cancer at the earliest stages, surpassing ctDNA approaches. It is low cost and high performing.

LEARN MORE:

University of California
San Francisco

Innovation Programs

UCSF Nancy Friend Pritzker Psychiatry Building

SKS

UCSF Quantitative Biosciences Institute

Cell Mapping Initiatives



Technology Development



Company Spin Outs

REZO

Investing in Diversity and Youth

QBI Scholarships

QBI Fellowships

Breaking down silos, building collaborations



Outreach and Events

About SOM Tech

BROAD TECHNOLOGY EXPERTISE

DEEP KNOWLEDGE OF THE UCSF ECOSYSTEM

HUMAN-CENTERED APPROACH

SOM Tech provides leadership and advocacy across the School of Medicine's technology spectrum, from research to data security to business process management.

Berkeley Space Center



The **UCSF Clinical Innovation Center** aims to accelerate innovations to solve the most critical care delivery issues.

Solve the right problem → **Solve the problem right**

Gain insight; understand the human and system factors

Identify the problem to solve and metric to shift

Challenge paradigms; develop prototypes

Refine, pilot and scale

For more information:

UCSF Center for Advanced 3D+ Technologies (CA3D+)



3D printing



Virtual surgical planning



Advanced visualization
Augmented/Virtual/Mixed Reality



https://ca3dplus.ucsf.edu/


We empower #healthtech entrepreneurs to deliver the future of #patient care.
We make getting to market easier for entrepreneurs by offering insider knowledge, mentorship, connections and access to funding
UCSF Rosenman Institute
Learn More!

The Mission

To improve the health, safety, and quality of life of pediatric patients by accelerating high-value, high impact pediatric device solutions at all stages of the total product lifecycle towards commercialization.

UCSF Team


Hanmin Lee, MD


Shuvo Roy, PhD


Usha Thekkedath, MD


Michael Harrison, MD


Willieford Moses, MD


Durga Pisharam, PhD

Accomplishments

- Consortium with longest history of FDA funding.
- Created a strong network of industry & academic partners and unique resources for pediatric innovations.
- Supported more than 300 pediatric device projects since 2009.
- Seed funding provided to more than 60 projects.
- Guided 13 device innovations to market, resulting in more than 25,000 children positively impacted.
- Helped secure more than $120M in follow on funding for portfolio projects.
- Pioneer in using real world evidence (RWE) to support a 510(k) labeled pediatric medical device indication.
- Provided Training and Professional Development opportunities to more than 60 students and fellows.

Funded by FDA Grant # P50FD007967

Learn More and Contact Us Here:

Health Innovation via Engineering

Completing the Circle of Innovation: Biology for Engineering

Robotics for High Throughput Science



Medical Implants

Engineering

Biology Health

Recording Video In DNA



Living Building Materials

engineering.ucsf.edu

UCSF Surgical Innovations
Departments of Surgery and
Bioengineering & Therapeutic Sciences

The Mission

To accelerate the translation of pioneering medical devices to improve patient care by lowering the barriers for surgeon-innovators,
Focusing on value-based solutions with market viability, and Educating trainees in interdisciplinary collaboration and translation

The Team

Hanmin Lee, MD
Clinical Director

Shuvo Roy, PhD
Technical Director

Usha Thekkedath, MD
Program Director

The Programs

- Weekly Innovators Forum
- Biodevice Innovation Fellowship Program
  - Two-year mentored research experience for surgical residents
- UCSF/UCB Masters of Translational Medicine
- Project Consultation for Faculty, Trainees, and UCSF-Affiliated Companies

Learn More and Contact Us Here:

SCAN ME

MASTER OF TRANSLATIONAL MEDICINE

Master of Translational Medicine
UC Berkeley - UC San Francisco

Translating biomedical discoveries into clinical reality.

The MTM program is a joint program between UC Berkeley and UCSF.

Scan for more

Berkeley
UNIVERSITY OF CALIFORNIA

UCSF
University of California
San Francisco